IFT46

Across TCGA pan-cancer cohorts, IFT46 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IFT46 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IFT46 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFT46 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where IFT46 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.860	1.000	.005	21	view →
CCRCC	OS	Quartile	III,IV	0.482	0.905	.017	6	view →
LUAD	OS	Median	III,IV	0.625	0.224	.024	5	view →
OV	DFS	Median	All	0.832	1.000	.015	4	view →
HNSC	OS	Median	IV	0.397	0.794	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IFT46–LSCC (DFS)

Open the LSCC breakdown →